A controversial study on the costs of unnecessary mammography, published in the April issue of Health Affairs, contains “serious methodological flaws,” said Richard Wender, chief cancer control officer at the American Cancer Society.
The U.S. spends $4 billion on unnecessary mammograms each year, according to a study published in the April issue of Health Affairs.
The Oncology Research Information Exchange Network, a partnership of academic cancer centers, has collected data from over 120,000 patients, and recently added four institutions.
Five years into the making of CancerLinQ, the American Society of Clinical Oncology is poised to become the next big player in oncology bioinformatics.
Introduction of biosimilar biologics will not bring about the same price drops as introduction of generic small-molecule drugs, said Rena Conti, an economist at the University of Chicago, whose work focuses on drug pricing.
The stochastic process of stem cell divisions should not be equated with bad luck, said Barnett Kramer, director of the NCI Division of Cancer Prevention, focusing on misinterpretations of the “Bad Luck” paper by Cristian Tomasetti and Bert Vogelstein, of Johns Hopkins University School of Medicine.
As Congress goes into recess and Democrats relinquish their eight-year control of the Senate, advocates for biomedical research are rethinking their approaches to a political reality not observed in nearly a decade: a Republican-controlled Congress.
As an oncologist who treats sarcoma, George Demetri has seen the adverse consequences of power morcellation, the surgical technique widely used to perform laparoscopic hysterectomies and remove putative fibroids.
The Cancer Letter asked Lawrence Einhorn, distinguished professor of medicine and the Livestrong Foundation Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, to reflect on one of the most spectacular successes in the history of cancer research—his development of the curative regimen for testicular cancer.
The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution's decision to close its 10-year-old proton beam center.
